News Releases

Taiho Pharmaceutical Co., Ltd. (TPC), a full-fledged oncology pharmaceutical company headquartered in Tokyo, announced on May 10 that it has established Taiho Ventures, LLC, a strategic corporate venture capital arm of TPC, in California, USA.

Taiho Ventures will be investing globally in the start-up companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. With the support of Taiho’s established expertise in the field of oncology product discovery and development, Taiho Ventures will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. Initially, Taiho Ventures will make investments from the pooled amount of US$ 50million.

In June 2014, TPC committed to invest US$ 30million in Remiges BioPharma Fund and through Remiges’ well-connected US-Japan cross border investment team, Taiho has been tapping into the US/Europe biotech start-up community to catalyze the company’s R&D. Establishing Taiho Ventures demonstrates our continuous commitment to create long-term relationships with external partners globally with the goal to bring novel cancer therapies to patients and redefine the way the world treats cancer.

Taiho Ventures is a wholly owned subsidiary of Taiho Oncology, Inc.

Company Name: Taiho Ventures, LLC
President: Sakae Asanuma
Head Office Location: California, US
Established: April 15, 2016
Business: Venture capital
Investment Scale: US$ 50million
Therapeutic Area of Investment:　Oncology
Geographic Area of Investment:　Globally with focus in U.S., Europe and Japan